Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Bronchogen

Bronchogen

Bronchogen 20 mg is a synthetic short regulatory peptide from the family of tissue-specific bioregulators of the Khavinson school, traditionally associated with the tetrapeptide Ala-Asp-Glu-Leu (ADEL) and attributed to the bronchopulmonary epithelium. Research Use Only.

47,99 €
With code BLACK: 38,39 € Lowest price in the 30 days before the discount: 47,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
Peptide Calculator

Bronchogen 20 mg - bronchial and lung bioregulator peptide (ADEL)

  • Bronchogen 20 mg is a synthetic short regulatory peptide from the family of tissue-specific bioregulators of the Khavinson school, traditionally associated with the tetrapeptide Ala-Asp-Glu-Leu (ADEL) and attributed to the bronchopulmonary epithelium.

As a research reagent, Bronchogen has never been registered as a medicinal product in the EU, US or other jurisdiction. It should be clearly distinguished from Taxorest — a peptide preparation from the Cytomax line available on the Russian market in the nutritional and regulatory category for the respiratory system. Bronchogen in reagent circulation – including in the lyophilisate vial format for reconstitution – is a Research Use Only material and it is not a substitute for a medicinal product or food.

No EMA/FDA authorization as a medicine and no EFSA authorization as a dietary supplement ingredient. Bronchogen it is not a cure for asthma, COPD or any respiratory disease — communicating the product as a “respiratory peptide”, “lung support”, “bronchial regeneration” or “natural respiratory medicine” is contrary to the Research Use Only framework.

Bronchogen is a synthetic short regulatory peptide derived from the concept peptide bioregulation developed in St. Petersburg Institute of Bioregulation and Gerontology under the supervision of Vladimir Khavinson. In this research school, Bronchogen belongs to the family of tissue-specific regulatory peptides (nomenclature ending in “-gene”), traditionally associated with a tetrapeptide with the sequence Ala-Asp-Glu-Leu (ADEL).

The conceptual assumption of the entire group is that short, several-amino acid peptides have affinity for the tissue from which they were originally isolated or to which their design concerns – in the case of Bronchogen, this is the bronchopulmonary epithelium and respiratory tissue. The reagent belongs to the line Endogenous — materials mapping molecules of endogenous origin or directly derived from them, provided for research on peptide bioregulation of respiratory tissue.

This reagent is supplied by Bronchogen in a 20 mg lyophilisate vials for self-reconstitution — dry powder that the researcher mixes into the working solution with bacteriostatic water according to the parameters of the planned experiment. The lyophilized format ensures longer durability of the material before dissolution and the freedom to select the working concentration, unlike ready-made solutions with a factory-set concentration. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

General description - peptide bioregulation in the Khavinson school

The concept of peptide bioregulation is based on the observation that short peptides composed of two to four amino acid residues can influence cell function in a tissue-specific manner. In a series of works (Khavinson 2002; Anisimov, Khavinson 2010), Vladimir Khavinson and colleagues hypothesized that these types of peptides are part of an internal regulatory system that controls gene expression in response to the functional state and age of the tissue.

Within this concept, the entire family was distinguished research peptides assigned to specific organs: pineal gland, thymus, vessels, heart, liver, pancreas, prostate – as well as bronchi and lungs, for which the working name has become Bronchogen. Mechanistically, this school proposes that short regulatory peptides enter the cell and then interact with specific sites in the DNA strand or with proteins that regulate transcription, thereby modulating the expression of genes relevant to a given cell type.

In tissue culture models, the effect of peptides of this family on the proliferation and differentiation of cells derived from the “mother” tissue of the peptide was observed (Chalisova et al. – tissue-specific peptide effects). The tissue specificity hypothesis is one of the most distinctive – and at the same time most controversial – elements of this concept, because it requires a mechanism for tissue recognition by a very short peptide sequence. More broadly, the Khavinson family of short regulatory peptides includes several recurring research themes:

  • Tissue-specific modulation of gene expression — hypothesis of the interaction of short peptides with DNA sequences and transcription factors
  • Effect on cell proliferation and differentiation in tissue cultures derived from the “parent” organ of the peptide
  • Cytoprotective and antioxidant effects in cellular models subjected to stress (oxidative, hypoxia, exposure to irritating factors)
  • Gerontological context — peptides as hypothetical modulators of processes related to tissue aging (Khavinson 2002; Anisimov, Khavinson 2010)
  • Short sequence and low molecular weight — tetra- and tripeptides, designed as fragments of larger tissue regulators

Bronchogen takes the place of a peptide in this family tissue-specific for the bronchopulmonary epithelium — tools to study the concept of peptide bioregulation of the respiratory tract cell, its protection, epithelial regeneration and stress resistance in experimental models. The same organ-specific logic is reflected in related line bioregulators: Cardiogen for heart tissue, Prostamax for the prostate, Livagen for the liver and Pancragen for the pancreas.

In the same line of respiratory bioregulators, the bioregulation school literature also considers an equivalent Taxorest (Cytomax line) – a product with separate marketing status in Russia, which should not be confused with a research reagent (distinction discussed below).

What is Bronchogen?

Chemically, Bronchogen is traditionally associated with a linear tetrapeptide with the sequence Ala-Asp-Glu-Leu. In vial format it is supplied as a 20 mg lyophilisate for self-reconstitution.

  • Common name: Bronchogen, bronchial/lung bioregulator peptide, respiratory peptide
  • Sequence (traditionally assigned): Ala-Asp-Glu-Leu (ADEL) – alanyl-asparaginyl-glutamyl-leucine; sequence for verification in the batch COA
  • Chemical class: synthetic short regulatory peptide (tetrapeptide); family of bioregulator peptides of the Khavinson school, tissue-specific lineage for the bronchopulmonary epithelium
  • CAS number: for verification in the batch COA
  • Molar mass: dependent on confirmed sequence; for the ADEL variant of approximately 446 g/mol (indicative value – the mass from the MS analysis of the batch is binding)
  • Delivered form: lyophilisate (sterile powder) in a vial, 20 mg; to be reconstituted with bacteriostatic water by the investigator; purity ≥98% HPLC
  • Conceptual origin: Khavinson’s concept of peptide bioregulation (St. Petersburg Institute of Bioregulation and Gerontology); Endogenic line; rotary equivalent: Taxorest (Cytomax line, Russia)

Characteristics table

Parameter Value Attention
Sequence Ala-Asp-Glu-Leu (ADEL) traditionally assigned – for verification in the COA
CAS number for verification in the batch COA identity is decided by the party’s MS
Molar mass approx. 446 g/mol (ADEL variant) indicative value; the MS mass is binding
Class respiratory regulatory tetrapeptide Khavinson bioregulator family
Character lyophilisate (white/off-white powder) 20 mg vial, for reconstitution
The mass of the peptide in the vial 20 mg before reconstitution
Cleanliness ≥98% HPLC UV detection, per batch verification
Rotary equivalent Taxorest (Cytomax, Russia) separate regulatory entity – not this reagent

Origin: Bronchogen originates from the tissue-specific peptide research program conducted at St. Petersburg Institute of Bioregulation and Gerontology. As part of this program, peptides were designed as short regulatory fragments assigned to specific organs, and then their effect on cells of a given tissue was examined in cultures and in animal models. Bronchogen was assigned to the bronchopulmonary epithelium and respiratory tissue.

It should be emphasized that the exact sequence and chemical identity of peptides of this family in the reagent trade may be inconsistent – therefore the sequence and molar mass of each batch of Bronchogen require confirmation in a certificate of analysis (COA), and the ADEL sequence is given as traditionally assigned, not as an unconditionally established identity of each material on the market.

Mechanism of action at the molecular level

Bronchogen is considered in the literature through the prism of the concept of tissue-specific peptide bioregulation. The following description refers to hypotheses and observations from preclinical models – not to a validated human clinical mechanism. Profile observed and postulated in preclinical models:

  1. Tissue-specific peptide bioregulation of the respiratory epithelium — the central hypothesis of the Khavinson school assumes that short regulatory peptides enter the cell and modulate gene expression by interacting with specific DNA sequences or with the transcription apparatus. In the case of Bronchogen, this concerns genes important for the function, survival and differentiation of bronchopulmonary epithelial cells; biophysical studies observed the influence of the Ala-Asp-Glu-Leu tetrapeptide itself on DNA thermal stability. Mechanism: postulated modulation of transcription, not classic stimulation of the membrane receptor (Khavinson 2002; Monaselidze et al. 2011)
  2. Modulation of respiratory epithelial function and local tissue response — the influence of peptides of this family on the function of epithelial cells, the integrity of the epithelial layer and the parameters of the local tissue response were studied in tissue culture models and respiratory tissue models; for Bronchogen, the research context is the functional condition of the respiratory epithelium in experimental conditions (Kuzubova et al. 2015 – bronchial epithelium peptide bioregulation)
  3. Antioxidant and anti-inflammatory effects in respiratory tissue — the protective potential of the peptide against cellular damage was tested in models of respiratory tissue subjected to oxidative stress or exposure to irritants; research context includes epithelial protection against reactive oxygen species and modulation of inflammatory markers in respiratory tissue
  4. Support for the regeneration of the respiratory epithelium — postulated impact on cell renewal parameters, reconstruction of the epithelial layer and survival of epithelial cells, considered in culture models as part of the general concept of bioregulation of respiratory tissue

Characteristics of peptides of this family (based on the literature of the bioregulation school):

  • Short sequence (tetrapeptide) and low molecular weight – typical for the designed regulatory fragments
  • Postulated ability to penetrate the cell and interact at the nuclear level – a hypothesis requiring further mechanistic verification
  • The action is described as modulatory and contextual, rather than classically stimulating – the peptide is intended to “normalize” cell function, not to force a one-way response
  • Human pharmacokinetic profile: not characterized for the reagent; no data from randomized clinical trials

Important distinction - Russian school, Bronchogen vs Taxorest, peptide vs respiratory drug

Three distinctions are critical here and must not be merged into one.

First – data origin. The concept of tissue-specific peptide bioregulation is an original, consistently developed achievement Russian scientific school (St. Petersburg Institute of Bioregulation and Gerontology). It is characterized by limited independent replication outside its home centers and much of the literature in Russian. The data for Bronchogen comes from cell and animal models – not large randomized clinical trials. This does not disqualify the concept, but sets a limit for interpretation: the observations are preliminary and require confirmation.

Second – Bronchogen (RUO reagent) vs Taxorest (marketable product). These are two separate regulatory entities. Taxorest is a peptide product from the Cytomax line available in the Russian market in the nutritional and regulatory category for the respiratory system. Bronchogen in the reagent trade, it is a Research Use Only material – a chemical reagent for laboratory research, without registration as a medicine or food in the EU, USA or other jurisdiction. Bronchogen RUO reagent is not a replacement Taxorest product and does not replace medical consultation or medicinal product.

Third – bioregulator peptide vs. drug for respiratory diseases. Bronchogen is not a cure for asthma, chronic obstructive pulmonary disease (COPD), respiratory infections or any other respiratory condition. Bioregulator peptide is a research tool for studies on the hypothesis of tissue-specific modulation of the respiratory epithelium – not a substitute for registered respiratory pharmacotherapy (inhaled glucocorticosteroids, bronchodilators, antibiotics, biological drugs). A person with respiratory symptoms requires diagnosis and treatment by a doctor; the research reagent has no use here.

Applications in scientific research

Bronchogen in the format of a lyophilized vial is used as a reagent in research work on the concept of peptide bioregulation of tissue-specific respiratory tissue, delivered in a form for independent reconstitution according to the experimental parameters. In vitro models (bronchial epithelial cultures, respiratory tissue cultures, models of oxidative stress and exposure to irritants) examine its impact on cell viability, epithelial regeneration, differentiation, and markers of oxidative damage and inflammation.

In vivo models (animal models used by bioregulation centers) examined the influence of peptides of this family on tissue parameters related to epithelial protection, regeneration and aging of respiratory tissue. Specific research directions include:

  • The concept of peptide tissue bioregulation — Bronchogen as a model tissue-specific peptide for the bronchopulmonary epithelium; testing the hypothesis of modulation of gene expression by short peptides in respiratory cells
  • Models of protection of the respiratory epithelium — assessment of the protective potential against oxidative stress and exposure to irritating factors in bronchial epithelium cultures
  • Epithelial regeneration studies — the effect of the peptide on cell renewal parameters, reconstruction of the epithelial layer and cell survival in culture models
  • Models of the inflammatory response in respiratory tissue — characterization of the effect of the peptide on inflammatory markers and local tissue response under experimental conditions
  • Experimental gerontology — bioregulatory peptides as tools for studying processes related to the aging of respiratory tissue (Anisimov, Khavinson 2010)
  • Independent and methodological verification — replication of observations of the bioregulation school in independent laboratories, including confirmation of the chemical identity and sequence of the tested material

Summary

Bronchogen 20 mg provides a synthetic short regulatory peptide (traditionally linked to the tetrapeptide Ala-Asp-Glu-Leu, ADEL) from the family of tissue-specific bioregulators of the Vladimir Khavinson school (St. Petersburg Institute of Bioregulation and Gerontology), Endogenic line – in the form of a 20 mg lyophilized vial for self-reconstitution with bacteriostatic water. The peptide is attributed to the bronchopulmonary epithelium, and the conceptual assumption is the modulation of airway cell gene expression by a short peptide – a hypothesis with four main themes: tissue-specific bioregulation of the respiratory epithelium, modulation of epithelial function and local tissue response, antioxidant/anti-inflammatory effects in respiratory tissue, and support for epithelial regeneration.

The whole concept remains mainly developed by the Russian school of science and is characterized by limited independent replication – data comes from cellular and animal models, without large randomized clinical trials. Bronchogen research reagent must be distinguished from a rotating product Taxorest (Cytomax line, Russia) and from a drug for respiratory diseases – Bronchogen is not a drug for asthma or COPD and does not replace respiratory pharmacotherapy.

Regulatory Status – Research Use Only; WADA status: class S0 (non-approved substances), prohibited at all times. The sequence of each batch requires confirmation with the COA.

Bibliography

  1. Khavinson VKh (2002). Peptides and Aging. PubMed
  2. Khavinson VK, Popovich IG, Linkova NS, et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. PubMed
  3. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. PubMed
  4. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. (2015). Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. PubMed
  5. Anisimov VN, Khavinson VKh (2010). Peptide bioregulation of aging: results and prospects. PubMed
  6. Chalisova NI, Linkova NS, Zhekalov AN, et al. (2015). Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. PubMed

Chemical reagent Research Use Only. Bronchogen 20 mg (Endogenic line) in the Pro-Body catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment. Bronchogen is a short bronchopulmonary bioregulator peptide of the Khavinson school, traditionally associated with the tetrapeptide Ala-Asp-Glu-Leu (ADEL) – sequence and mass confirmed by mass spectrometry in the batch COA conclusively determine the identity.

Bronchogen it is not registered as a medicine in the EU or the US, it is not a cure for asthma, COPD or any other respiratory disease and does not replace registered respiratory pharmacotherapy; it should be distinguished from the Taxorest rotary product (Cytomax line). The information in the description is of an educational and scientific nature and refers to observations reported in preclinical literature – it does not constitute medical advice or administration instructions.